Ocriplasmin: who is the best candidate?

Claudia M Prospero Ponce, William Stevenson, Rachel Gelman, Daniel R Agarwal, John B Christoforidis Retina Division, Department of Ophthalmology, University of Arizona Medical Center, Tucson, AZ, USA Abstract: Enzymatic vitreolysis is currently the focus of attention around the world for treating...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Prospero Ponce CM, Stevenson W, Gelman R, Agarwal DR, Christoforidis JB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Vitreomacular traction Macular Hole Enzymatic vitreolysis Ocriplasmin-Best candidate Diabetic macular edema future management Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/513dc210827f4837993822f0cad7cf35
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:513dc210827f4837993822f0cad7cf35
record_format	dspace
spelling	oai:doaj.org-article:513dc210827f4837993822f0cad7cf352021-12-02T06:38:11ZOcriplasmin: who is the best candidate?1177-5483https://doaj.org/article/513dc210827f4837993822f0cad7cf352016-03-01T00:00:00Zhttps://www.dovepress.com/ocriplasmin-who-is-the-best-candidate-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Claudia M Prospero Ponce, William Stevenson, Rachel Gelman, Daniel R Agarwal, John B Christoforidis Retina Division, Department of Ophthalmology, University of Arizona Medical Center, Tucson, AZ, USA Abstract: Enzymatic vitreolysis is currently the focus of attention around the world for treating vitreomacular traction and full-thickness macular hole. Induction of posterior vitreous detachment is an active area of developmental clinical and basic research. Despite exerting an incompletely elucidated physiological effect, ocriplasmin (also known as microplasmin) has been recognized to serve as a well-tolerated intravitreal injection for the treatment of vitreomacular traction and full-thickness macular hole. There are several unexplored areas of intervention where enzymatic vitreolysis could potentially be used (ie, diabetic macular edema). Recent promising studies have included combinations of enzymatic approaches and new synthetic molecules that induce complete posterior vitreous detachment as well as antiangiogenesis. Although no guidelines have been proposed for the use of ocriplasmin, this review attempts to aid physicians in answering the most important question, “Who is the best candidate?” Keywords: vitreomacular traction, macular hole, enzymatic vitreolysis, ocriplasmin-best candidate, diabetic macular edema, future managementProspero Ponce CMStevenson WGelman RAgarwal DRChristoforidis JBDove Medical PressarticleVitreomacular tractionMacular HoleEnzymatic vitreolysisOcriplasmin-Best candidateDiabetic macular edemafuture managementOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 485-495 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Vitreomacular traction Macular Hole Enzymatic vitreolysis Ocriplasmin-Best candidate Diabetic macular edema future management Ophthalmology RE1-994
spellingShingle	Vitreomacular traction Macular Hole Enzymatic vitreolysis Ocriplasmin-Best candidate Diabetic macular edema future management Ophthalmology RE1-994 Prospero Ponce CM Stevenson W Gelman R Agarwal DR Christoforidis JB Ocriplasmin: who is the best candidate?
description	Claudia M Prospero Ponce, William Stevenson, Rachel Gelman, Daniel R Agarwal, John B Christoforidis Retina Division, Department of Ophthalmology, University of Arizona Medical Center, Tucson, AZ, USA Abstract: Enzymatic vitreolysis is currently the focus of attention around the world for treating vitreomacular traction and full-thickness macular hole. Induction of posterior vitreous detachment is an active area of developmental clinical and basic research. Despite exerting an incompletely elucidated physiological effect, ocriplasmin (also known as microplasmin) has been recognized to serve as a well-tolerated intravitreal injection for the treatment of vitreomacular traction and full-thickness macular hole. There are several unexplored areas of intervention where enzymatic vitreolysis could potentially be used (ie, diabetic macular edema). Recent promising studies have included combinations of enzymatic approaches and new synthetic molecules that induce complete posterior vitreous detachment as well as antiangiogenesis. Although no guidelines have been proposed for the use of ocriplasmin, this review attempts to aid physicians in answering the most important question, “Who is the best candidate?” Keywords: vitreomacular traction, macular hole, enzymatic vitreolysis, ocriplasmin-best candidate, diabetic macular edema, future management
format	article
author	Prospero Ponce CM Stevenson W Gelman R Agarwal DR Christoforidis JB
author_facet	Prospero Ponce CM Stevenson W Gelman R Agarwal DR Christoforidis JB
author_sort	Prospero Ponce CM
title	Ocriplasmin: who is the best candidate?
title_short	Ocriplasmin: who is the best candidate?
title_full	Ocriplasmin: who is the best candidate?
title_fullStr	Ocriplasmin: who is the best candidate?
title_full_unstemmed	Ocriplasmin: who is the best candidate?
title_sort	ocriplasmin: who is the best candidate?
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/513dc210827f4837993822f0cad7cf35
work_keys_str_mv	AT prosperoponcecm ocriplasminwhoisthebestcandidate AT stevensonw ocriplasminwhoisthebestcandidate AT gelmanr ocriplasminwhoisthebestcandidate AT agarwaldr ocriplasminwhoisthebestcandidate AT christoforidisjb ocriplasminwhoisthebestcandidate
_version_	1718399812847534080

Ocriplasmin: who is the best candidate?

Ejemplares similares